Medpace Holdings, Inc. (MEDP) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Medpace Holdings, Inc. (MEDP) Healthcare & Pipeline Overview

Medpace Holdings, Inc. is a global clinical research organization providing comprehensive drug and medical device development services. With a focus on Phase I-IV clinical trials, Medpace serves pharmaceutical, biotechnology, and medical device companies across North America, Europe, and Asia, distinguishing itself through integrated service offerings and therapeutic expertise.

What Is the Investment Thesis for MEDP?

Medpace Holdings, Inc. presents a compelling investment case based on its strong market position in the growing CRO industry. The company's focus on providing comprehensive clinical development services, from Phase I to Phase IV, positions it to capitalize on the increasing demand for outsourced research and development. With a P/E ratio of 34.0 and a profit margin of 17.2%, Medpace demonstrates solid profitability. Key growth catalysts include expansion into new therapeutic areas and continued geographic expansion. Potential risks include increased competition in the CRO market and regulatory changes affecting clinical trials. The company's high beta of 1.39 suggests higher volatility compared to the market.

Based on FMP financials and quantitative analysis

MEDP Key Highlights

Market capitalization of $17.1B reflects investor confidence in Medpace's growth prospects and market leadership.

• P/E ratio of 34.0 indicates a premium valuation, suggesting high expectations for future earnings growth.
• Profit margin of 17.2% demonstrates strong profitability and efficient operations within the competitive CRO landscape.
• Gross margin of 29.1% highlights the company's ability to manage costs effectively while delivering high-value services.
• The company has 5900 employees, reflecting its substantial operational scale and global reach in supporting clinical trials.

Who Are MEDP's Competitors?

MEDP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are MEDP's Key Strengths?

Comprehensive service offerings across the clinical development process.

• Strong expertise in various therapeutic areas.
• Global presence with operations in North America, Europe, and Asia.
• Experienced management team with a proven track record.

What Are MEDP's Weaknesses?

Reliance on the pharmaceutical, biotechnology, and medical device industries.

• Exposure to regulatory changes and compliance requirements.
• Potential for delays and setbacks in clinical trials.
• High beta indicating higher volatility compared to the market.

What Could Drive MEDP Stock Higher?

MEDP catalyst: Expansion into new therapeutic areas, such as gene therapy and personalized medicine, driving revenue growth.

• Geographic expansion in the Asia-Pacific region, providing access to new markets and clients.
• Potential acquisitions and partnerships to expand service offerings and geographic reach.
• Increased adoption of technology in clinical trials, improving efficiency and cost-effectiveness.
• Focus on rare diseases and orphan drugs, attracting clients developing therapies for underserved populations.

What Are the Key Risks for MEDP?

Rich valuation — a P/E of 34.0 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.

• Increased competition from other CROs, potentially impacting market share and pricing.
• Economic downturns affecting R&D spending in the pharmaceutical industry, reducing demand for clinical research services.
• Changes in regulatory requirements for clinical trials, increasing compliance costs and complexity.
• Reliance on key clients and therapeutic areas, creating concentration risk.
• Potential for delays and setbacks in clinical trials, impacting revenue and profitability.

What Are the Growth Opportunities for MEDP?

• Expansion into New Therapeutic Areas: Medpace has the opportunity to expand its service offerings into new and emerging therapeutic areas such as gene therapy and personalized medicine. These areas are experiencing rapid growth and require specialized clinical trial expertise. By investing in these areas, Medpace can attract new clients and increase its market share. The market size for gene therapy is projected to reach $25 billion by 2030, presenting a significant growth opportunity.
• Geographic Expansion in Asia-Pacific: The Asia-Pacific region represents a significant growth opportunity for Medpace due to its large population, increasing healthcare spending, and growing pharmaceutical industry. Expanding its presence in countries like China and India can provide access to a large pool of patients and clinical trial sites. This expansion can be achieved through strategic partnerships and acquisitions. The Asia-Pacific CRO market is expected to grow at a CAGR of 12% over the next five years.
• Increased Adoption of Technology in Clinical Trials: The increasing adoption of technology in clinical trials, such as remote monitoring and data analytics, presents an opportunity for Medpace to enhance its service offerings and improve efficiency. By investing in these technologies, Medpace can offer clients more efficient and cost-effective clinical trial solutions. The market for clinical trial technology is expected to reach $10 billion by 2028.
• Strategic Acquisitions and Partnerships: Medpace can pursue strategic acquisitions and partnerships to expand its service offerings and geographic reach. Acquiring companies with complementary expertise or entering into partnerships with leading research institutions can enhance Medpace's competitive position and attract new clients. This strategy can accelerate growth and provide access to new markets and technologies. The company has a history of successful acquisitions and partnerships.
• Focus on Rare Diseases and Orphan Drugs: The increasing focus on rare diseases and orphan drugs presents a significant growth opportunity for Medpace. Clinical trials for rare diseases often require specialized expertise and smaller patient populations, which aligns with Medpace's capabilities. By focusing on this area, Medpace can differentiate itself from larger CROs and attract clients developing therapies for rare diseases. The market for orphan drugs is expected to reach $250 billion by 2028.

What Are MEDP's Competitive Advantages?

• Specialized expertise in clinical trial design and execution.
• Strong relationships with pharmaceutical, biotechnology, and medical device companies.
• Global presence with operations in North America, Europe, and Asia.
• Integrated service offerings covering the entire clinical development process.

What Does MEDP Do?

Founded in 1992 and headquartered in Cincinnati, Ohio, Medpace Holdings, Inc. has evolved into a leading clinical research organization (CRO) providing a full suite of services to the pharmaceutical, biotechnology, and medical device industries. The company supports clinical development programs from Phase I through Phase IV, offering expertise across a broad range of therapeutic areas. Medpace's services include clinical trial design, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance, and new drug application submissions. It also provides specialized services such as bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support. Medpace operates in North America, Europe, and Asia, providing global reach for its clients' clinical development needs. The company differentiates itself through its integrated service offerings, therapeutic expertise, and commitment to scientific rigor, aiming to accelerate drug and medical device development timelines.

What Products and Services Does MEDP Offer?

• Provides clinical research-based drug development services.
• Offers clinical research-based medical device development services.
• Supports clinical development from Phase I to Phase IV.
• Offers development plan design services.
• Provides coordinated central laboratory services.
• Offers project management services for clinical trials.
• Manages regulatory affairs and submissions.
• Provides clinical monitoring and data management services.

How Does MEDP Make Money?

• Provides clinical trial management services to pharmaceutical, biotechnology, and medical device companies.
• Generates revenue through fees for services related to clinical trial design, execution, and analysis.
• Offers specialized services such as bio-analytical laboratory services and clinical human pharmacology.

What Industry Does MEDP Operate In?

Medpace operates within the global clinical research organization (CRO) industry, which is experiencing steady growth driven by increasing R&D spending in the pharmaceutical and biotechnology sectors. The market is competitive, with key players like Centene Corporation (CNC), Quest Diagnostics Incorporated (DGX), and Illumina, Inc. (ILMN). Medpace differentiates itself through its focus on scientific rigor, therapeutic expertise, and integrated service offerings. The CRO industry is expected to continue growing as pharmaceutical companies increasingly outsource clinical trial activities to improve efficiency and reduce costs.

Who Are MEDP's Key Customers?

• Pharmaceutical companies developing new drugs.
• Biotechnology companies researching and developing innovative therapies.
• Medical device companies seeking regulatory approval for their products.
• Academic research institutions conducting clinical trials.

Company Profile

Medpace Holdings, Inc. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Cincinnati, US. The company is led by CEO August James Troendle. MEDP has traded publicly since 2016.

Medpace Holdings, Inc. Financial Trajectory

Medpace Holdings, Inc. (MEDP) reported $707.3M in revenue for Q2 2026, reflecting 0.1% growth compared to the prior quarter. The company recorded net income of $121.4M, with diluted EPS of $4.25. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, MEDP averaged $4.27 in diluted EPS.

How Medpace Holdings, Inc. Is Valued

Medpace Holdings, Inc. carries a market capitalization of $17.1B, placing it in the large-cap category. Relative to its peer group, MEDP's quantitative score of 94/100 is above the peer average of 67/100.

Return on equity for Medpace Holdings, Inc. stands at 120.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 21.6%, showing how much profit it generates from its asset base. MEDP trades at a trailing price-to-earnings ratio of 34.03, above the Healthcare sector average of ~23x. Its free cash flow yield is 4.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.85 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 2.9%, the inverse of the P/E and a quick read on earnings relative to price.

Medpace Holdings, Inc.'s Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 7.81 places it in the safe zone, indicating low near-term bankruptcy risk.

Medpace Holdings, Inc. has beaten Wall Street's EPS estimate in 8 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 11.6% above estimates on average.

Wall Street analysts project Medpace Holdings, Inc. revenue of about $2.85B for fiscal 2026, with EPS near $17.60. The estimate reflects 9 contributing analysts.

Over the past six months, Medpace Holdings, Inc. insiders filed 27 SEC Form 4 transactions — 7 sales and 20 purchases. On net that is roughly 65K shares acquired (about $15.9M) — insiders putting money in tends to read as conviction.

MEDP Financials

MEDP Latest News

MEDP Analyst Consensus

MEDP MoonshotScore

Latest Medpace Holdings, Inc. Analysis

MEDP Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources